Oncology

Latest News

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com

Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

By AJMC Contributor

May 12th 2025

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 25th 2015

Molecularly Targeted SHIVA Trial Fails to Improve Outcomes in Refractory Cancer Patients

Surabhi Dangi-Garimella, PhD

The trial, conducted in France, was a proof-of-concept study to evaluate the efficacy of targeted agents in patients, based on their tumor's molecular profile.

September 25th 2015

The Dawning of Democratized Cancer Care

Emmanuel F. Petricoin III, PhD

Innovative trials offer the promise that patients can be treated in their own communities instead of traveling to faraway cancer centers.

September 24th 2015

Startup's Direct-to-Consumer Genetic Test Receives FDA Attention

Surabhi Dangi-Garimella, PhD

In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.

September 24th 2015

ASCO President Julie Vose, MD, to Give Keynote at AJMC's Patient-Centered Oncology Care Meeting

The fourth annual meeting of Patient-Centered Oncology Care, set for November 19-20, 2015, in Baltimore, Maryland, will feature a premiere multi-stakeholder lineup where leading payers, providers, and leaders from pharma will discuss how to deliver value-based care as cost of breakthrough therapies continues to climb. Julie Vose, MD, MBA, FASCO, the president of the American Society of Clinical Oncology, will give the keynote address.

September 24th 2015

USPSTF Recommendation May Increase Risk for Prostate Cancer

Surabhi Dangi-Garimella, PhD

A study published in The Journal of Urology suggests the Grade D recommendation for PSA-based screening may place those with intermediate and high-risk prostate cancer at risk.

Dr Julie Vose on the Importance of Attending PCOC15

September 23rd 2015

Dr Julie Vose on the Importance of Attending PCOC15

Julie Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology and keynote speaker at Patient-Centered Oncology Care 2015, explains the importance of the meeting and how patients benefit when a diverse set of stakeholders come together in one room.

September 23rd 2015

Dissecting the Patient Perception of FDA's Breakthrough Designation

Surabhi Dangi-Garimella, PhD

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

September 23rd 2015

Clinton Seeks Cap on Drug Expenses, Would Let Medicare Negotiate

Mary K. Caffrey

Hillary Clinton unveiled a plan in Iowa that features a $250 per month cap on drug costs for patients with chronic conditions. This comes 2 weeks after her chief rival for the Democratic nomination, US Senator Bernie Sanders of Vermont, introduced a bill aimed at reining in drug costs. In the summer, The American Journal of Managed Care said polling showed that rising drug costs were poised to become a major issue in the 2016 campaign.

September 23rd 2015

Physicians Believe in Biosimilars but Lack Awareness, Says Report by Quantia

Surabhi Dangi-Garimella, PhD

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

September 22nd 2015

Lonsurf Granted Approval for Advanced Colorectal Cancer

Surabhi Dangi-Garimella, PhD

Lonsurf (TAS-102) is an oral 2-drug combination pill that is intended for metastatic colorectal cancer patients who have failed on chemotherapy and biological therapy.

September 22nd 2015

AstraZeneca Believes Open Innovation Will Uncover Novel Anticancer Combinations

Surabhi Dangi-Garimella, PhD

AstraZeneca hopes to harness the open source platform of the DREAM challenge, releasing preclinical data to discover synergistic cancer drug combinations.

September 21st 2015

Reimbursement Challenges Persist as Oncologists Embrace Value-Based Care, ACCC Survey Finds

Surabhi Dangi-Garimella, PhD

Among other challenges faced by cancer care centers, reimbursement for providing patient-centered care services remains at the top, a survey by The Association of Community Cancer Centers found.

September 21st 2015

New FDA Nominee May Face Challenges for His Pharma Ties

Surabhi Dangi-Garimella, PhD

A report in The New York Times identifies challenges that could be raised based on Califf's past associations with the drug industry.

September 20th 2015

About Half with Cancer Want to Discuss Care Costs with Physician, But Fewer Do, Study Finds

Rising costs in cancer care, especially for new therapies, have gained attention in recent years. However, a study just published in The American Journal of Managed Care finds about half of patients are interested in discussing cost on the front end, but only a minority actually have a cost discussion with their oncologist.

Dr Clifford Goodman Peers 20 Years Into the Future of NCCN

September 20th 2015

Dr Clifford Goodman Peers 20 Years Into the Future of NCCN

As the National Comprehensive Cancer Network (NCCN) celebrates 20 years, Clifford Goodman, PhD, takes a look at how NCCN will evolve after another 20 years, including constant streaming of real-time data and more patient involvement.

This Week in Managed Care: September 19, 2015

September 19th 2015

This Week in Managed Care: September 19, 2015

The top stories in managed care include the nomination for the next FDA commissioner, a report reveals cancer drugs are driving growth in the 340B program more than initially thought, and nearly half a billion in ACA funds are made available to health centers.

September 18th 2015

Tumor Response Signature to Bevacizumab Recognized in HER2-Negative Breast Cancer

Surabhi Dangi-Garimella, PhD

A collaborative team of researchers have been able to identify a gene signature that can predict how HER2-negative breast cancer patients would respond to treatment with bevacizumab.

September 18th 2015

NIH Approves Blueprint for Obama's Precision Medicine Initiative

Surabhi Dangi-Garimella, PhD

The path to President Obama's Precision Medicine Initiative has been paved as is evident from a report released by a Working Group convened by the National Institutes of Health.

September 17th 2015

MAF Regulates Bone Metastases in Breast Cancer

Surabhi Dangi-Garimella, PhD

Scientists in Spain have identified gene mutations that trigger bone metastasis in breast cancer patients.

September 17th 2015

The Cost Conundrum in Cancer Care

Surabhi Dangi-Garimella, PhD

At the recently held NCCN healthcare policy summit in Washington, DC, experts delved into various models being evaluated to reduce healthcare utilization in oncology care.

September 16th 2015

An Open Discussion on Value in Oncology Care at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD

Healthcare policy makers, payers, medical centers, and patient representatives shared the dais as they discussed The Value Proposition in oncology.

September 16th 2015

Bim Expression Could Predict Patient Response to PD-1 Blockade, Mayo Clinic Study Finds

Surabhi Dangi-Garimella, PhD

Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.

September 16th 2015

Participating Faculty: Management of Advanced/Metastatic Melanoma: New and Emerging Treatment Pathways, Therapies, and Challenges [CPE]

September 15th 2015

Cancer Drugs Driving 340B Growth Even More Than Understood, Report Finds

Mary K. Caffrey

The report, commissioned by the Community Oncology Alliance, finds that Medicare Part B cancer drug spending rose 123% in 340B hospitals from 2010 to 2013, but only 31% in non-340B hospitals; it fell 5% in community practices in the same period.

September 15th 2015

Interoperability Important for Better Outcomes: ASCO to Congress

The American Society of Clinical Oncology has urged Congress to recognize the impact of barriers to interoperability of electronic health records on patient outcomes.

September 15th 2015

In Conversation With an Oncologist: 340B and Its Impact on the Community

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.

September 14th 2015

Demographic Factors Influence Survival in Younger Patients With Leukemia

Surabhi Dangi-Garimella, PhD

The study, published in the journal Cancer, found that non-biological factors are as important as biological variables in shaping outcomes in young patients with leukemia.

Dr Peter Bach Explains How Increasing Drug Prices Stifle Innovation

September 14th 2015

Dr Peter Bach Explains How Increasing Drug Prices Stifle Innovation

The ability to charge increasingly higher prices for drugs that already have competition on the market is stifling innovation and wasting resources and human subjects, according to Peter Bach, MD, MAPP, director of Memorial Sloan Kettering Cancer Center's Center for Health Policy and Outcomes.

September 14th 2015

California "Aid-in-Dying" Bill Awaits Governor's Decision

Mary K. Caffrey

Supporters say the bill would bring choice and dignity to those suffering, while opponents say the poor will be pressured by family members and heirs to take their lives because healthcare is too expensive.

September 14th 2015

Care Access, Centers of Excellence, and the ACA: Expert Interchange at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD

Healthcare policy experts gathered in Washington, DC, to discuss access, cost, and the definition of value in oncology care.

...

120 121 122 123 124 125 126 127 128

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions